“It is known that men who have prostate cancer are more likely to die of their disease if they are overweight or obese than if they are of a healthy weight,” according to Dr Stephen Finn, Associate Professor in Histopathology and Morbid Anatomy in Trinity College Dublin and Consultant Pathologist at St James’s Hospital.
Two new studies, both published in The Lancet, suggest that two different classes of drugs, aromatase inhibitors (AIs) and bisphosphonates, can each improve survival prospects for postmenopausal women with early breast cancer.
New Irish research published in BMJ Open has found that young people aged 16-17 years old believe standardised packs to be less attractive and their cigarettes to be more harmful than packs with EU Tobacco Products Directive (TPD) labels, which includes picture and text warning covering 65 per cent of the packages.
In the largest prospective study to date of image-guided technology for identifying suspicious regions of the prostate to biopsy, researchers compared the ability of this technology to detect high-risk prostate cancer with that of the current standard of unguided prostate biopsy.
In the years to come, personalised medicine will be the goal, Gary Culliton reports in his latest Clinical Update. It is a promising area: now much effort is devoted to studying combinations of different therapies.
Colorectal cancer is a treatable disease and there are a number of effective options available. Progress has been made in diagnosing the disease earlier. Data on which treatment works best in the early stages of the cancer is now being sought.
Bowel cancer survival has more than doubled in the last 40 years. But much work remains. Key partners have come together to develop new ways to tailor treatment to the patients who will benefit the most, and to make a difference to their chances of beating this common disease.
Clearly, not every prostate cancer patient will benefit from novel endocrine treatments, Gary Culliton reports in his latest Clinical Update. Thus, personalised medicine is key. The challenge now is to identify which patients will benefit from the drugs and which will not.
Researchers at Trinity College Dublin and Mount Sinai in New York have published new research, which for the first time provides strong evidence on the economic benefits of early palliative care intervention for people with an advanced cancer diagnosis.
Men with a high fitness level in mid-life appear to be at lower risk for lung and colorectal cancer, but not prostate cancer, and that higher fitness level also may put them at lower risk of death if they are diagnosed with cancer when they’re older, according to a study published online by JAMA Oncology.